Stock Ratings / Health Care / TRIB / dividends

CDIO (31) BMRA (39) QCLS (42) VRAX (58) ⌘ Pro Terminal →

Trinity Biotech plc (TRIB) Dividend Safety Gauge & 10-Year DRIP Compounder

$6.63 -2.50% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.59

Trinity Biotech plc (TRIB) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $5.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.59 (-0.64%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY • 51.8% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE-0.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TRIB)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (56/100 Composite)

🔍 WHY TRIB SCORES 56/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (27% of score)

FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 38.2 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$6.86+17.1% Next Q

Q2 (-2Q)

Grade C$8.03-9.1% Next Q

Q3 (-1Q)

Grade C$7.30-9.2% Next Q

Current

Grade D+$6.63-0.4% Hist 90D α

Trajectory: C+ (64) → D+ (56)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the TRIB Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 56/100 (D+) score, TRIB faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($7.69) or 200D SMA ($15.42) invalidates the momentum regime and cuts Target Base ($6.57) toward Bear Floor ($5.12).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TRIB• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “TRIB Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 56%NO 44%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TRIB)

✓Walkthrough of TRIB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TRIB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -63.17%⚡ TESTING RESISTANCE

2026-10-30O $6.43H $6.63L $6.26C $6.63VOL 6.7K

RES: $7.79SUP: $3.69SMA50: $7.69SMA200: $15.42

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TRIB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TRIB Butterfly Map → + Track TRIB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TRIB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TRIB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TRIB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TRIB)

Health Care Rank #270 of 1016 ⚔️ CDIO vs TRIB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TRIB vs. CDIO, BMRA, QCLS, VRAX)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Trinity Biotech plc (TRIB) ranks #270 by composite RQD confidence (56/100, grade D+) and #940 by equity capitalization ($5.4M). Within this direct 5-issuer industry benchmark cohort, TRIB leads on earnings valuation at N/A trailing P/E, while CDIO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. VRAX currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with TRIB at 56/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TRIB ACTIVE Trinity Biotech plc	D+	56/100	—	—	—	-2.50%	$5.4M	Benchmark Subject
CDIO Cardio Diagnostics Holdings Inc.	E	31/100	—	—	-35.0%	+2.94%	$5.2M	/cdio-vs-trib →
BMRA Biomerica Inc.	D-	39/100	—	8.1%	-35.0%	-0.57%	$8.0M	/bmra-vs-trib →
QCLS Q/C Technologies Inc.	D-	42/100	—	—	-35.0%	-3.44%	$3.6M	/qcls-vs-trib →
VRAX Virax Biolabs Group Limited	D+	58/100	—	—	—	+10.00%	$1.8M	/vrax-vs-trib →

2. TRIB Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Trinity Biotech plc (TRIB) operates in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care) with an equity capitalization of $5.4M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. TRIB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TRIB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Trinity Biotech plc (NASDAQ: TRIB) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $6.63 (-2.50% 1D, market cap $5.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, TRIB ranks #270 in composite RQD confidence.

How does TRIB compare to CDIO and BMRA in the Health Care sector?

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), TRIB carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CDIO (Cardio Diagnostics Holdings Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $5.2M) and BMRA (Biomerica Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $8.0M). Among the 5-stock peer group, TRIB leads on earnings multiple (N/A) while CDIO leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TRIB?

For Trinity Biotech plc (TRIB), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #270 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TRIB trading relative to its 50-day, 200-day, and 52-week technical levels?

TRIB last traded at $6.63 (-2.50% on volume of 26,700 shares), positioning the stock -13.78% below its 50-day simple moving average ($7.69) and -57.00% below its 200-day simple moving average ($15.42). Across its 52-week range of $5.01 to $52.50, TRIB sits at the 3.4% percentile with a 14-day RSI of 38.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.80 to $7.46).

TRIB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does TRIB pay a dividend and is it safe?

Trinity Biotech plc (TRIB) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: TRIB RQD Cockpit TRIB 12M Forecast TRIB Earnings & Move TRIB Dividends & DRIP TRIB Insiders & 13F TRIB Whale Options TRIB Profit Sankey TRIB News & Why